Skip to content
TrialScanner

NCT02689284

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Phase 1/Phase 2CompletedMGNXLeadMRKCollaborator

Registry record

Lead sponsor
MacroGenics
Conditions
Gastric Cancer; Stomach Cancer; Esophageal Cancer
Primary completion
Jan 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02689284 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02689284: Combination Margetuximab and... | TrialScanner